Doxorubicin HCL Cas 25316-40-9

Chemical Name: Doxorubicin HCL
CAS No.: 25316-40-9
Molecular Formula: C27H30ClNO11
Molecular Weight:579.98
Appearance:Orange-Red Crystalline powder

  ... 正在查看此商品

  分享
Guaranteed Safe Checkout

Table of Contents

Doxorubicin HCl (CAS 25316-40-9) Technical Specifications

Key Parameters

Parameter Specification
Chemical Name (8S,10S)-10-[(3-Amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione hydrochloride
CAS Number 25316-40-9
Molecular Formula C₂₇H₂₉NO₁₁·HCl
Purity ≥98% (HPLC, USP/EP standards)
Storage 2-8°C protected from light
Shelf Life 24 months in original packaging

Therapeutic Agent Comparison Matrix

Feature Doxorubicin HCl Epirubicin Daunorubicin
Antineoplastic Spectrum Broadest (solid & hematologic tumors) Moderate (breast/ovarian focus) Narrow (leukemia focus)
Cardiotoxicity Risk High (dose-dependent) Moderate High
Standard Dosage 60-75 mg/m² 100-120 mg/m² 30-45 mg/m²
FDA-Approved Uses 13 cancer types 6 cancer types 4 cancer types

Oncology Applications & Mechanisms

Clinical Indications

  • First-line treatment in metastatic breast cancer (AC regimen)
  • Hodgkin’s/Non-Hodgkin’s lymphoma (CHOP protocol)
  • Acute lymphoblastic leukemia (hyper-CVAD cycles)

Research Frontiers

  • Liposomal encapsulation studies (reduced cardiotoxicity)
  • Combination with immune checkpoint inhibitors
  • Nano-carrier delivery systems (enhanced tumor targeting)

Operational Protocol & Risk Management

Infusion Guidelines

Parameter Requirement
Reconstitution Use only 0.9% NaCl solution
Infusion Rate 30-60 minutes (per 50mg)
Incompatible Agents Heparin sodium, Dexamethasone

Toxicity Monitoring

  • Cardiac: LVEF monitoring every 3 cycles
  • Hematologic: ANC counts pre-cycle
  • Dermatologic: Palmar-plantar erythrodysesthesia grading

Documented Use Cases (2023-2024)

Case 1: Shanghai Cancer Center

  • Application: Triple-negative breast cancer neoadjuvant therapy
  • Regimen: Dose-dense AC-T (4 cycles Doxorubicin 60mg/m² + Cyclophosphamide)
  • Outcome: 68% pathologic complete response rate

Case 2: Singapore Biotech Ltd.

  • Research: pH-sensitive nanoparticle delivery system
  • Result: 40% tumor accumulation improvement vs. free drug
  • Current Phase: IND-enabling studies

Request Customized Solutions

Contact our oncology specialists for:

  • Bulk API procurement (GMP/CEP certified)
  • Clinical trial material support
  • Formulation development services

Email: info@vivalr.com
Tel: (86) 15866781826
Office Hours: Mon-Fri 8:30 AM – 5:30 PM CST

0.00
0 条评论
5
0
4
0
3
0
2
0
1
0
成为第一个评论 “Doxorubicin HCL Cas 25316-40-9”

您的邮箱地址不会被公开。 必填项已用 * 标注

这是必填栏。

这是必填栏。

这是必填栏。

评论

目前还没有评论。

类别 
我的购物车
愿望清单
最近浏览
类别
Wait! before you leave…
Get 30% off for your first order
CODE30OFFCopy to clipboard
Use above code to get 30% off for your first order when checkout
比较产品 (0 产品)